Revolution in early diagnosis

The cascade of misfolding of alpha-Synuclein (α-Syn) is a central molecular event in the development of Parkinson's disease. Under physiological conditions, α-Syn is largely unfolded and soluble. However, due to genetic mutations, oxidative stress, or environmental factors, it can undergo conformational changes that promote β-sheet–rich structures like oligomers and fibrils. Infrared (IR) spectroscopy provides a powerful readout to track this progression. The amide I band (1700–1600 cm⁻¹) is particularly sensitive to protein secondary structures. Thus, the transition can be followed by distinct IR frequencies, which act as molecular fingerprint, enabling real-time monitoring of α-Syn misfolding and aggregation associated with Parkinson´s Disease progression.

At the core of the iRS is an inert biochip surface designed to inhibit nonspecific binding and background signals, ensuring that only the intended target molecules are immobilized while preserving their structural integrity for precise spectral analysis. A highly specific antibody anchored to the surface selectively captures the biomarker—such as different conformers of α-Syn—from complex samples. The bound protein is then analyzed via the amide I infrared region, allowing clear discrimination between physiological and disease-associated conformations. By integrating inert surface chemistry, antibody-based specificity, and structural IR readout, the iRS enables sensitive, label-free detection of conformational biomarkers. This positions the technology as a powerful platform for the detection and monitoring of misfolding biomarkers across a broad range of protein aggregation diseases.